Lakefront Biotherapeutics (LKFT) Return on Sales [ROS] (2014 - 2026)
Lakefront Biotherapeutics' Return on Sales [ROS] was -358.92% in the quarter ended Jun 30, 2026, down 271.67 percentage points from -87.25% a year earlier but up 624.00 percentage points from the prior quarter.
Lakefront Biotherapeutics (LKFT) Return on Sales [ROS] (2014 - 2026) Analysis & Trends
On a trailing twelve-month basis, Lakefront Biotherapeutics' Return on Sales [ROS] was 40.59% through Jun 30, 2026, up 139.65 percentage points year-over-year; for the year ended Dec 31, 2025, it was 26.53%, up 94.85 percentage points from the prior year.
- Return on Sales [ROS] shows a five-year change of +63.89 percentage points (years ended Dec 2020 to Dec 2025).
- In earlier years, Return on Sales [ROS] was -68.33% in the year ended Dec 31, 2024 (-31.51 pp), -36.82% in the year ended Dec 31, 2023 (+17.51 pp), -54.32% in the year ended Dec 31, 2022 (+18.88 pp) and -73.20% in the year ended Dec 31, 2021 (-35.83 pp).
- Quarterly Return on Sales [ROS] has moved between -982.92% (the quarter ended Mar 31, 2026) and 190.13% (the quarter ended Dec 31, 2024) over five years.
- Compared with a year earlier, Return on Sales [ROS] has declined for six straight quarters, with an average year-over-year change of -201.26 percentage points over the last eight quarters.
- The best year-over-year quarter for Return on Sales [ROS] over five years was the quarter ended Dec 31, 2024 (a gain of 150.17 percentage points); the worst was the quarter ended Mar 31, 2026 (a drop of 771.24 percentage points).
- Per Business Quant data, LKFT's Return on Sales [ROS] in the three quarters before the quarter ended Jun 30, 2026 was -982.92% (quarter ended Mar 31, 2026), 84.06% (quarter ended Dec 31, 2025) and -346.51% (quarter ended Sep 30, 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 28.21% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 28.37% |
| 10 | Lakefront Biotherapeutics | 1.94 Bn | 1.94 Bn | 3.51 Mn | -358.92% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -358.92% |
| Mar 31, 2026 | -982.92% |
| Dec 31, 2025 | 84.06% |
| Sep 30, 2025 | -346.51% |
| Jun 30, 2025 | -87.25% |
| Mar 31, 2025 | -211.68% |
| Dec 31, 2024 | 190.13% |
| Sep 30, 2024 | -119.07% |
| Jun 30, 2024 | 42.10% |
| Mar 31, 2024 | -53.07% |
| Dec 31, 2023 | 39.96% |
| Sep 30, 2023 | -23.23% |
| Jun 30, 2023 | -22.49% |
| Mar 31, 2023 | -24.24% |
| Dec 31, 2022 | -52.48% |
| Sep 30, 2022 | -27.58% |
| Jun 30, 2022 | -55.47% |
| Mar 31, 2022 | -15.51% |
| Dec 31, 2021 | -54.70% |
| Sep 30, 2021 | -55.27% |
Lakefront Biotherapeutics Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=LKFT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "LKFT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=LKFT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();